U.S. Centers for Disease Control and Prevention



V-safe: CDC's newest vaccine safety monitoring system

Anne Hause, PhD, MSPH

Immunization Safety Office

Centers for Disease Control and Prevention (CDC)

Advisory Commission on Childhood Vaccines

January 30, 2025

Disclaimer

- The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the official position of the CDC
- Mention of a product or company name is for identification purposes only and does not constitute endorsement by CDC
- Information about COVID-19 vaccination approvals, authorizations, and clinical guidance is current as of the dates listed in this presentation, but may change in the future

CDC vaccine safety monitoring

CDC monitors the safety of vaccines using strong, complementary systems both new and established



Vaccine Adverse Event Reporting System (VAERS), Vaccine Safety Datalink (VSD), Clinical Immunization Safety Assessment (CISA)

Establishing the first generation of V-safe

V-safe was established to help monitor the safety of COVID-19 vaccines

- Safety monitoring for authorized or approved COVID-19 vaccines in the United States
- Established December 2020 through donated services from Oracle Corporation
- Goals:
 - Rapidly provide data from recently vaccinated persons to CDC
 - Provide reactogenicity data during the first week after vaccination

V-safe: smartphone-based vaccine safety monitoring

- Self-registration on smartphone at vsafe.cdc.gov
- Used text messages that link to web surveys
- Surveys were brief requiring less than a minute to complete
- Available languages: English, Spanish, Chinese, Korean, and Vietnamese



Health surveys included questions about local and systemic reactions and health events

- Surveys sent daily during the week following each dose of vaccine then weekly through 6 weeks and at 3, 6, and 12 months
- Questions solicited adverse events and health impacts after COVID-19 vaccination
- Daily surveys asked questions about
 - Local reactions (e.g., injection site pain)
 - Systemic reactions (e.g., fatigue)
 - Health impacts (e.g., medical care)
- Surveys included questions to identify participants potentially interested in and eligible for a pregnancy registry



V-safe facilitated reporting of medically attended events to VAERS



V-safe was updated over time to reflect policy changes

- Additional manufacturers
- Dependent feature
- Simultaneous vaccination
- Booster doses
- Surveys for young children
- (V-safe for Mpox)

	-1					
his date? *	ai vaccine(s) did yo	u receive of				
Don't remer	mber/prefer not to s	ay				
Flu (influen:	za)					
Tetanus (Td	Tetanus (Tdap or Td)					
Shingles						
Pneumonia						
HPV						
Meningitis						
Monkeypox						
Other						
	Next >					
	< Go Back					
	Cancel					

How data are used

• Presentations:

- V-safe data are regularly presented to the Advisory Committee on Immunization Practices and other stakeholders

Publications:

- Our goal is to rapidly provide data to the public via publications like MMWR
- Over 25 publications to date (<u>https://pubmed.ncbi.nlm.nih.gov/collections/64312280/?sort=pubdate</u>)

• Public data sharing:

- V-safe datasets are available at https://data.cdc.gov

Key contributions of V-safe to COVID-19 vaccine safety

From December 2020 through June 2023, over 10 million persons participated in V-safe



*V-safe identified pregnant people for enrollment in Vaccine Pregnancy Registry | CDC

Use of V-safe data

Adverse reactions and health impacts reported by adults aged ≥18 years who received a homologous Moderna (N = 307,998), or Pfizer-BioNTech (N = 332,588) COVID-19 vaccine booster, by dose



Hause AM, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022. MMWR Morb Mortal Wkly Rep 2022.

Challenges

- V-safe for COVID-19 relied on donated services from Oracle Corporation
- Limitation: without access to the survey-building software, responding quickly to new vaccination campaigns (e.g. Mpox) was difficult
- Free text responses were challenging to analyze
 - Received >7.6 million free text responses
 - Natural language processing results were nonspecific
 - Required a new contract to MedDRA code responses for analysis
- V-safe (first generation) operations concluded June 2023

Conclusions

- V-safe complements the existing vaccine safety surveillance systems
 - Rapidly provides data on reactogenicity during the week after vaccination
- V-safe greatly contributed to COVID-19 vaccine safety monitoring
 - Describing reactogenicity in the days following vaccination
 - Facilitating reports of medically attended adverse events to VAERS
 - Identifying pregnant women for enrollment in the pregnancy registry
- Given its success, a smartphone-based survey system can be utilized for other vaccine campaigns

Establishing the second generation of V-safe

Second generation of V-safe established Fall 2023

- Most changes were to the system
 - Adaptable: easy to add new vaccination protocols
 - Responsive: able to respond quickly to health concerns
 - Configurable: supports complex survey logic
- User experience is similar
 - First generation V-safe users must create a new account
 - Demographic and contact information collected at registration
 - Includes both email and text messaging functionality
- Vaccines currently monitored:
 - RSV vaccines for older adults (est. October 2023)
 - RSV vaccines for pregnant persons (est. December 2023)
 - COVID-19 vaccines for persons aged 6 months and older (est. January 2024)



Participants enroll in specific vaccine protocols

V-safe						Vsafe Testname 💌	Help	😚 English 🔻		
Home Health Check-ins Vaccination History My Account										
Vsafe Testname 1 Dependent 1 Testname	Dependent2 Testname Vie	ew More Add D	Pependent							
Hello, Vsafe Testname										
	Has Vsafe Testname received a new vaccine? To enter a new vaccine, click "Erroll". To add another dose , select from the table below.									
	Enrolled Activities for To add another dose, select	Vsafe Testname t from the table below.			DOWNLOAD CSV					
	Enrolled Activities	To Do	Date Enrolled	Vaccine Date	Notification Preferences					
	RSV for 60 years and older		10/20/2023	10/20/2023	=					
	COVID-19 💿		02/15/2024	02/15/2024	E					

- Can enroll in multiple protocols simultaneously
- Can enroll dependents
- Can view pending actions and navigate to dependent profiles

New questions included to determine baseline health

- Each vaccine protocol includes questions about a participant's health at the time of vaccination
 - Immunocompromise
 - Current state of health
 - Healthcare utilization in past year

/-sa	fe	
	Medical history	
	* At the time of vaccination, were you immunocompromised? Refers to most recent COVID-19 vaccine received.	
	O Yes 🚯	
	No No	
	O Unknown/prefer not to answer	
	How would you describe your current state of health? Excellent	
	O Very good	
	O Good	
	O Fair	
	O Poor	
	During the past 12 months, how many times have you seen a doctor or other healthcare professional about your health at a doctor's office, a clinic, or some other place?	
	O None	
	O 1	
	O 2-3	
	0 4-5	
	0 6-7	
	O 8-9	
	O 10-12	
	O 13-15	
	O 16 or more	
	O Do not know/cannot recall	

Health surveys vary slightly by vaccine protocol

- Surveys are sent daily during the first week, then weekly through 6 weeks after vaccination
 - Daily surveys ask questions about
 - Local reactions (e.g., injection site pain)
 - Systemic reactions (e.g., fatigue)
 - Health impacts (e.g., medical care)
 - Worsening of symptoms for persons who reported immunocompromise at vaccination
- Weekly surveys solicit new symptoms or conditions after vaccination



Maternal RSV vaccine protocol includes additional surveys and questions

- History of preterm delivery
- Current pregnancy
 - High-risk status
 - Multiplicity
 - Estimated of delivery
 - Date of delivery
 - If infant received nirsevimab for RSV

=7		
* Are you currently p	egnant?	
Refers to pregnancy during	/hich you received the RSV vaccine.	
() Yes		
No		
* When was your dat	e of delivery?	
02/09/2024		
* Did your infant rec	ive nirsevimab (Beyfortus) for RSV prevention?	
Yes		
O No		
O No		
No * When did your infa	t receive nirsevimab (Beyfortus)?	
No * When did your infa Select a date 02/19/2024	it receive nirsevimab (Beyfortus)?	

COVID-19 surveys include specific questions for children aged <2 years



۱n ^ا	the past 24 hours, did Testdependent
nav	e any of these symptoms? Report
nev	v symptoms noted after vaccination.
Pleas	ect all that apply.
out t	hey aren't a problem. Moderate = symptoms limit
10rm 10rm	al daily activities. Severe = symptoms make al daily activities difficult or impossible.
	Sleepiness
	Irritability/crying
	Loss of appetite
	Vomiting
	Diarrhea
	Rash, not including the
	immediate area around the
	injection site
	Other
	None

V-safe facilitates reporting to VAERS

- Participants reporting a medically attended health impact are prompted to complete a VAERS report
- May opt to prepopulate select fields in the VAERS report with information provided to V-safe

=7					
By selecting "Yes" below, you authorize V-safe to share your information with the Vaccine Adverse Event Reporting System (VAERS). Please review your information and provide additional details before submitting your VAERS report.					
	Yes, continue to VAERS website to complete my report.	No, please exit			

VAERS Vaccine.	Adverse Event Reporting s.hhs.gov	System					
About VAERS Repo	rt an Adverse Event	VAERS Data	a ~	Reso	ources ~	•	Submit Follow-Up Information
Completion Status	Report an Adverse E	vent - Patien	t Informat	ion			Instructions en Español
Patient Information	Note: Fields marked with	an * are essenti	al and should	be com	pleted.		
Reporter Information	ltem 1 😧						
Facility Information	Patient first name:				Patient last	name:	
Vaccine Information							
Additional Information	Street address:						
VAERS	City:		State:		~		County:
Repertor Information	Zip code: Phon			ne:			Email:
Fadily Information	Item 2 😧				Item 3 🕻)	
Vaccine Inflavroofian	* Date of birth 💽 mm/dd/	te of birth (🛃 mm/dd/yyyy) or 📃 mm/yyyy)			* Sex:		
Additional information	mm/dd/yyyy			#	○ Male ○	Female	· ○ Unknown
Click to preview VAERS form	Item 4 😧						
	* Date of vaccination 🕑 mm/dd/yyyy	mm/dd/yyyy or [mm/yyyy)	**	Time: hh:mm		⊙ ам ⊙ рм
	Item 5 😧						
	* Date adverse event star	ted 📿 mm/dd/v	vvv or 🗆 mr	n/vvvv)	Time:		

https://vaers.hhs.gov/esub/index.jsp

Challenges and next steps

- Challenges:
 - Improving participation
 - More diverse population of respondents
- Next steps:
 - Continued surveillance of new vaccines
 - Engaging vaccination providers
 - New methods of promotion

Increasing V-safe participation – We need your help

- Ensure vaccination partners are aware of V-safe
 - Information sheets
 - Social media posts
 - Communications to vaccine recipients
- Vaccines currently monitored:
 - RSV vaccines for older adults and pregnant persons
 - COVID-19 vaccines for persons aged 6 months and older
- Materials and more information available at:

https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/v-safe/index.html

What is V-safe?

V-safe is an innovative vaccine safety monitoring system that allows you or your dependent to quickly and easily share how you feel after getting a vaccine. It takes just a few minutes to enroli, and then you will receive V-safe notifications through text messages or emails to complete short, contidential health check-ins. Your participation in V-safe makes a difference—it helps others know what to expect in the days following vaccination, and it helps CDC monitor the safety of vaccines for everyone.

V-safe features:

- Receive health check-ins via text or email after vaccination.
- Enroll your dependents and complete check-ins on their behalf.
- Share how you feel after getting a vaccine dose.

How can I enroll, and how does it work?

V-safe is available for several vaccines. Go to vsafe.cdc.gov to find out if you are eligible to enroil. If you are eligible, tollow the prompts to register for V-safe health check-ins. During the first week after vaccination, V-safe will send you a text message or email notification each day to ask how you are feeling. Then you will get check-in messages once a week for up to 5 weeks. Depending on your answers, V-safe may send you a link to submit a report in the Vaccine Adverse Event Reporting System (VAERS).

You can opt out at any time by texting "STOP" when V-safe sends you a text message or by clicking "unsubscribe" when V-safe sends you an email. You can also opt back in by changing your preferred method of contact, found in your user profile. Your personal information in V-safe is protected so that it stays confidential and private."

How can I enroll my dependent?

To enroll a dependent in V-safe, add them to your existing account, or create a new account if you don't have one yet. Enrolling a dependent does not require you to enter your own vaccination information or complete health check-ins for yourself.

Need step-by-step instructions? Go to: www.cdc.gov/vsafe

"V-safe gathers data employing strict security measures appropriate for the data twevior of exmittivity. These measures comply, where applicable, with the biolowing federal laws including the Privacy Act of 1944, administration exclude that are consistent with the Headt Insurance Portability and Accountability Act of 1996 (HPAN), the Federal information Security Management Act, and the Federal of Information Act.



Sign up with your smartphone, tablet, or computer at <u>vsafe.cdc.gov</u>

OR

Aim your smartphone's camera at this code



Need help with V-safe?

Call 1-833-748-1979

Email CARS HelpDesk@cdc.gov

> Visit www.cdc.gov/vsafe



Acknowledgements

• VAERS and V-safe teams

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U. S. Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.



25